The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.